Invictus RG’s AbbVie ABBV Stock Holding History

Invictus RG’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-237	Closed	-$15K	–	612
2017 Q1	$15K	Buy	+237	New	+$14.9K	0.01%	622

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invictus RG's ABBV Position: Q2 2017 in Review

Invictus RG sold out of AbbVie (ABBV) in Q2 2017, closing a stake of 237 shares — an estimated $15K sold.

Invictus RG first reported a position in ABBV in Q1 2017 and held it in 1 quarter. The position peaked at $15K in Q1 2017. 1,763 funds tracked by Wall St. Rank hold ABBV as of Q2 2017.

Invictus RG reported no remaining AbbVie position as of Q2 2017 after selling out during the quarter.
Invictus RG sold 237 AbbVie shares in Q2 2017, an estimated $15K.
Invictus RG first reported a position in AbbVie in Q1 2017 and held it in 1 quarter.
Invictus RG's AbbVie position peaked at $15K in Q1 2017.
1,763 funds tracked by Wall St. Rank held AbbVie as of Q2 2017.

Based on Invictus RG's 13F filing for Q2 2017, filed 14 Aug 2017.